Dr. Kariadi Central General Hospital
Semarang, Central of Java, Indonesia
NCT Number: NCT06573684
The goal of this clinical trial is to learn the differences severity level of diabetic neuropathy based on electromyelography in type II diabetic patient with and without comorbidities. The main questions of this study:
1. What is the electromyography result in type II diabetic patient who: has no comorbidities, with hypertension, with hypertension and dyslipidemia? 2. Is there any differences in electromyography result in type II diabetic patient who: has no comorbidities, with hypertension, with hypertension and dyslipidemia? 3. Is there any association between distal latency with nerve conduction velocity in type II diabetic patient with and without comorbidities? 4. Is there any association between distal latency with amplitude in type II diabetic patient with and without comorbidities? 5. Is there any differences on diabetic neuropathy severity based on age, height, and A1C levels in type II diabetic patient with and without comorbidities?
Researchers will collect information based on hospital registry as secondary data of in type II diabetic patient with and without comorbidities. The data consist of demographic data, clinical presentation, laboratory, and electromyography were collected from hospital registry by reviewing medical record. Then, the data was analyzed by using IBM SPSS Statistics v26.
Looking for future studies?
Notify Me40 year–80 year
All sexes
Observational
Semarang, Central of Java, Indonesia
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
All of groups will have assessment of electromyography result
Time frame: Electromyography examination was done approximately 1 year after clinical onset of neuropathy appear
Distal latency defined as time between stimuli until deflection of Compound Muscle Action Potentials (CMAP) from baseline
Time frame: Electromyography examination was done approximately 1 year after clinical onset of neuropathy appear
Nerve Conduction Velocity defined as the measurement of axon conduction velocity by dividing space of nerve conduction with time needed
Time frame: Electromyography examination was done approximately 1 year after clinical onset of neuropathy appear
Amplitude define as the height of first negative deflection of Compound Muscle Action Potentials (CMAP) from baseline
Universitas Diponegoro
Other
Acronym: DISNEY-T2DM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06292962
Diabetes Complications, Diabetes Mellitus
Lahore, Pakistan
View Trial DetailsNCT06482827
Diabetes Complications, Diabetes Mellitus
Hamilton, Ontario, Canada
View Trial DetailsNCT05683106
Cardiovascular Diseases, Diabetes Complications
São Paulo, Brazil
View Trial DetailsNCT06025422
Cardiovascular Diseases, Diabetes Complications
Leicester, Leicestershire, United Kingdom
View Trial Details